---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-067644"
form_type: "8-K"
ticker: "IDYA"
cik: "0001676725"
company_name: "IDEAYA Biosciences, Inc."
filed_at: "2024-06-03T23:59:59+00:00"
generated_at: "2026-06-01T06:50:49.880421+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# IDEAYA darovasertib Phase 2 uveal melanoma data: 75% eye saved, 47% median tumor shrinkage

## Summary
- Investigator-sponsored Phase 2: 75% of enucleation patients (9/12) had eye saved (converted to brachytherapy/EBRT) after 6 months.
- Median tumor shrinkage 47% (max volume change) in 12 enucleation patients; 67% had >30% shrinkage after 6 months.
- Company-sponsored Phase 2: 8 patients at ≥4 months showed median tumor volume shrinkage 72%; majority of enucleation patients converted to eye saved.
- Drug-related AEs predominantly Grade 1-2; no drug-related serious AEs in either trial.
- Data presented at ASCO 2024; trial enrolled over 40 patients across 14+ sites globally.

## SEC filing metadata
- accession: 0000950170-24-067644
- form_type: 8-K
- ticker: IDYA
- cik: 0001676725
- company_name: IDEAYA Biosciences, Inc.
- filed_at: 2024-06-03T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1676725/000095017024067644/0000950170-24-067644-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1676725/000095017024067644/idya-20240603.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-067644
- JSON: https://secwatch.observer/filing/0000950170-24-067644.json
- Plain text: https://secwatch.observer/filing/0000950170-24-067644.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.